Antibody microarray

Last updated
Samples of antibody microarray creations and detections. Antibody microarray scheme.jpg
Samples of antibody microarray creations and detections.

An antibody microarray (also known as antibody array) is a specific form of protein microarray. In this technology, a collection of captured antibodies are spotted and fixed on a solid surface such as glass, plastic, membrane, or silicon chip, and the interaction between the antibody and its target antigen is detected. Antibody microarrays are often used for detecting protein expression from various biofluids including serum, plasma and cell or tissue lysates. Antibody arrays may be used for both basic research and medical and diagnostic applications. [1] [2] [3] [4]

Contents

Background

The concept and methodology of antibody microarrays were first introduced by Tse Wen Chang in 1983 in a scientific publication [5] and a series of patents, [6] [7] [8] when he was working at Centocor in Malvern, Pennsylvania. Chang coined the term “antibody matrix” and discussed “array” arrangement of minute antibody spots on small glass or plastic surfaces. He demonstrated that a 10×10 (100 in total) and 20×20 (400 in total) grid of antibody spots could be placed on a 1×1 cm surface. He also estimated that if an antibody is coated at a 10 μg/mL concentration, which is optimal for most antibodies, 1 mg of antibody can make 2,000,000 dots of 0.25 mm diameter. Chang's invention focused on the employment of antibody microarrays for the detection and quantification of cells bearing certain surface antigens, such as CD antigens and HLA allotypic antigens, particulate antigens, such as viruses and bacteria, and soluble antigens. The principle of "one sample application, multiple determinations", assay configuration, and mechanics for placing absorbent dots described in the paper and patents should be generally applicable to different kinds of microarrays. When Tse Wen Chang and Nancy T. Chang were setting up Tanox, Inc. in Houston, Texas in 1986, they purchased the rights on the antibody matrix patents from Centocor as part of the technology base to build their new startup. Their first product in development was an assay, termed “immunosorbent cytometry”, [9] which could be employed to monitor the immune status, i.e., the concentrations and ratios of CD3 +, CD4 +, and CD8 + T cells, in the blood of HIV-infected individuals.

The theoretical background for protein microarray-based ligand binding assays was further developed by Roger Ekins and colleagues in the late 1980s. [10] [11] [12] According to the model, antibody microarrays would not only permit simultaneous screening of an analyte panel, but would also be more sensitive and rapid than conventional screening methods. Interest in screening large protein sets only arose as a result of the achievements in genomics by DNA microarrays and the Human Genome Project.

The first array approaches attempted to miniaturize biochemical and immunobiological assays usually performed in 96-well microtiter plates. While 96-well plate-based antibody arrays have high-throughput capability, the small surface area in each well limits the number of antibody spots and thus, the number of analytes detected. Other solid supports, such as glass slides and nitrocellulose membranes, were subsequently utilized to develop arrays which could accommodate larger panels of antibodies. [13] Nitrocellulose membrane-based arrays are flexible, easy to handle, and have increased protein binding capacity, but are less amenable to high throughput or automated processing. Chemically derivatized glass slides allow for printing of sub-microliter sized antibody spots, reducing the array surface area without sacrificing spot density. This in turn reduces the volume of sample consumed. Glass slide-based arrays, owing to their smooth and rigid structure, can also be easily fitted to high-throughput liquid handling systems.

Most antibody array systems employ 1 of 2 non-competitive methods of immunodetection: single-antibody (label-based) detection and 2-antibody (sandwich-based) detection. The latter method, in which analyte detection requires the binding of 2 distinct antibodies (a capture antibody and a reporter antibody, each binding to a unique epitope), confers greater specificity and lower background signal compared with label-based immunodetection (where only 1 capture antibody is used and detection is achieved by chemically labeling all proteins in the starting sample). Sandwich-based antibody arrays usually attain the highest specificity and sensitivity (ng – pg levels) of any array format; their reproducibility also enables quantitative analysis to be performed. [14] [15] Due to the difficulty of developing matched antibody pairs that are compatible with all other antibodies in the panel, small arrays often make use of a sandwich approach. Conversely, high-density arrays are easier to develop at a lower cost using the single antibody label-based approach. In this methodology, one set of specific antibodies is used and all the proteins in a sample are labelled directly by fluorescent dyes or haptens.

Initial uses of antibody-based array systems included detecting IgGs and specific subclasses, [16] [17] analyzing antigens, [18] screening recombinant antibodies, [19] [20] studying yeast protein kinases, [21] analyzing autoimmune antibodies, [22] and examining protein-protein interactions. [23] [24] [25] The first approach to simultaneously detect multiple cytokines from physiological samples using antibody array technology was by Ruo-Pan Huang and colleagues in 2001. [26] Their approach used Hybond ECL membranes to detect a small panel of 24 cytokines from cell culture conditioned media and patient's sera and was able to profile cytokine expression at physiological levels. Huang took this technology and started a new business, RayBiotech, Inc., the first to successfully commercialize a planar antibody array.

In the last ten years, the sensitivity of the method was improved by an optimization of the surface chemistry as well as dedicated protocols for their chemical labeling. [27] Currently, the sensitivity of antibody arrays is comparable to that of ELISA [28] [29] and antibody arrays are regularly used for profiling experiments on tissue samples, plasma or serum samples and many other sample types. One main focus in antibody array based profiling studies is biomarker discovery, specifically for cancer. [30] [31] [32] [33] [34] For cancer-related research, the development and application of an antibody array comprising 810 different cancer-related antibodies was reported in 2010. [35] Also in 2010, an antibody array comprising 507 cytokines, chemokines, adipokines, growth factors, angiogenic factors, proteases, soluble receptors, soluble adhesion molecules, and other proteins was used to screen the serum of ovarian cancer patients and healthy individuals and found a significant difference in protein expression between normal and cancer samples. [36] More recently, antibody arrays have helped determine specific allergy-related serum proteins whose levels are associated with glioma and can reduce the risk years before diagnosis. [37] Protein profiling with antibody arrays have also proven successful in areas other than cancer research, specifically in neurological diseases such as Alzheimer's. A number of studies have attempted to identify biomarker panels that can distinguish Alzheimer's patients, and many have used antibody arrays in this process. Jaeger and colleagues measured nearly 600 circulatory proteins to discover biological pathways and networks affected in Alzheimer's and explored the positive and negative relationships of the levels of those individual proteins and networks with the cognitive performance of Alzheimer's patients. [38] Currently the largest commercially available sandwich-based antibody array detects 1000 different proteins. [39] In addition, antibody microarray based protein profiling services are available analyzing protein abundance and protein phosphorylation or ubiquitinylation status of 1030 proteins in parallel. [40]

Antibody arrays are often used for detecting protein expression from many sample types, but also in those with various preparations. Jiang and colleagues illustrated nicely the correlation between array protein expression in two different blood preparations: serum and dried blood spots. [41] These different blood sample preparations were analyzed using three antibody array platforms: sandwich-based, quantitative, and label-based, and a strong correlation in protein expression was found, suggesting that dried blood spots, which are a more convenient, safe, and inexpensive means of obtaining blood especially in non-hospitalized public health areas, can be used effectively with antibody array analysis for biomarker discovery, protein profiling, and disease screening, diagnosis, and treatment.

Applications

Using antibody microarray in different medical diagnostic areas has attracted researchers attention. Digital bioassay is an example of such research domains. In this technology, an array of microwells on a glass/polymer chip are seeded with magnetic beads (coated with fluorescent tagged antibodies), subjected to targeted antigens and then characterised by a microscope through counting fluorescing wells. A cost-effective fabrication platform (using OSTE polymers) for such microwell arrays has been recently demonstrated and the bio-assay model system has been successfully characterised. [42] Furthermore, immunoassays on thiol-ene "synthetic paper" micropillar scaffolds have shown to generate a superior fluorescence signal. [43]

See also

Related Research Articles

<span class="mw-page-title-main">Proteomics</span> Large-scale study of proteins

Proteomics is the large-scale study of proteins. Proteins are vital parts of living organisms, with many functions such as the formation of structural fibers of muscle tissue, enzymatic digestion of food, or synthesis and replication of DNA. In addition, other kinds of proteins include antibodies that protect an organism from infection, and hormones that send important signals throughout the body.

<span class="mw-page-title-main">ELISA</span> Method to detect an antigen using an antibody and enzyme

The enzyme-linked immunosorbent assay (ELISA) is a commonly used analytical biochemistry assay, first described by Eva Engvall and Peter Perlmann in 1971. The assay uses a solid-phase type of enzyme immunoassay (EIA) to detect the presence of a ligand in a liquid sample using antibodies directed against the protein to be measured. ELISA has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries.

<span class="mw-page-title-main">Microarray</span> Small-scale two-dimensional array of samples on a solid support

A microarray is a multiplex lab-on-a-chip. Its purpose is to simultaneously detect the expression of thousands of biological interactions. It is a two-dimensional array on a solid substrate—usually a glass slide or silicon thin-film cell—that assays (tests) large amounts of biological material using high-throughput screening miniaturized, multiplexed and parallel processing and detection methods. The concept and methodology of microarrays was first introduced and illustrated in antibody microarrays by Tse Wen Chang in 1983 in a scientific publication and a series of patents. The "gene chip" industry started to grow significantly after the 1995 Science Magazine article by the Ron Davis and Pat Brown labs at Stanford University. With the establishment of companies, such as Affymetrix, Agilent, Applied Microarrays, Arrayjet, Illumina, and others, the technology of DNA microarrays has become the most sophisticated and the most widely used, while the use of protein, peptide and carbohydrate microarrays is expanding.

<span class="mw-page-title-main">Western blot</span> Analytical technique used in molecular biology

The western blot, or western blotting, is a widely used analytical technique in molecular biology and immunogenetics to detect specific proteins in a sample of tissue homogenate or extract. Besides detecting the proteins, this technique is also utilized to visualize, distinguish, and quantify the different proteins in a complicated protein combination.

<span class="mw-page-title-main">Biochip</span> Substrates performing biochemical reactions

In molecular biology, biochips are engineered substrates that can host large numbers of simultaneous biochemical reactions. One of the goals of biochip technology is to efficiently screen large numbers of biological analytes, with potential applications ranging from disease diagnosis to detection of bioterrorism agents. For example, digital microfluidic biochips are under investigation for applications in biomedical fields. In a digital microfluidic biochip, a group of (adjacent) cells in the microfluidic array can be configured to work as storage, functional operations, as well as for transporting fluid droplets dynamically.

<span class="mw-page-title-main">Immunohistochemistry</span> Common application of immunostaining

Immunohistochemistry (IHC) is the most common application of immunostaining. It involves the process of selectively identifying antigens (proteins) in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. IHC takes its name from the roots "immuno", in reference to antibodies used in the procedure, and "histo", meaning tissue. Albert Coons conceptualized and first implemented the procedure in 1941.

<span class="mw-page-title-main">Immunoassay</span> Biochemical test for a protein or other molecule using an antibody

An immunoassay (IA) is a biochemical test that measures the presence or concentration of a macromolecule or a small molecule in a solution through the use of an antibody (usually) or an antigen (sometimes). The molecule detected by the immunoassay is often referred to as an "analyte" and is in many cases a protein, although it may be other kinds of molecules, of different sizes and types, as long as the proper antibodies that have the required properties for the assay are developed. Analytes in biological liquids such as serum or urine are frequently measured using immunoassays for medical and research purposes.

A protein microarray is a high-throughput method used to track the interactions and activities of proteins, and to determine their function, and determining function on a large scale. Its main advantage lies in the fact that large numbers of proteins can be tracked in parallel. The chip consists of a support surface such as a glass slide, nitrocellulose membrane, bead, or microtitre plate, to which an array of capture proteins is bound. Probe molecules, typically labeled with a fluorescent dye, are added to the array. Any reaction between the probe and the immobilised protein emits a fluorescent signal that is read by a laser scanner. Protein microarrays are rapid, automated, economical, and highly sensitive, consuming small quantities of samples and reagents. The concept and methodology of protein microarrays was first introduced and illustrated in antibody microarrays in 1983 in a scientific publication and a series of patents. The high-throughput technology behind the protein microarray was relatively easy to develop since it is based on the technology developed for DNA microarrays, which have become the most widely used microarrays.

<span class="mw-page-title-main">Immunoproteomics</span>

Immunoproteomics is the study of large sets of proteins (proteomics) involved in the immune response.

<span class="mw-page-title-main">Anti-dsDNA antibodies</span> Group of anti-nuclear antibodies

Anti-double stranded DNA (Anti-dsDNA) antibodies are a group of anti-nuclear antibodies (ANA) the target antigen of which is double stranded DNA. Blood tests such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence are routinely performed to detect anti-dsDNA antibodies in diagnostic laboratories. They are highly diagnostic of systemic lupus erythematosus (SLE) and are implicated in the pathogenesis of lupus nephritis.

A reverse phase protein lysate microarray (RPMA) is a protein microarray designed as a dot-blot platform that allows measurement of protein expression levels in a large number of biological samples simultaneously in a quantitative manner when high-quality antibodies are available.

<span class="mw-page-title-main">Proximity ligation assay</span>

Proximity ligation assay is a technology that extends the capabilities of traditional immunoassays to include direct detection of proteins, protein interactions, extracellular vesicles and post translational modifications with high specificity and sensitivity. Protein targets can be readily detected and localized with single molecule resolution and objectively quantified in unmodified cells and tissues. Utilizing only a few cells, sub-cellular events, even transient or weak interactions, are revealed in situ and sub-populations of cells can be differentiated. Within hours, results from conventional co-immunoprecipitation and co-localization techniques can be confirmed.

Immunomics is the study of immune system regulation and response to pathogens using genome-wide approaches. With the rise of genomic and proteomic technologies, scientists have been able to visualize biological networks and infer interrelationships between genes and/or proteins; recently, these technologies have been used to help better understand how the immune system functions and how it is regulated. Two thirds of the genome is active in one or more immune cell types and less than 1% of genes are uniquely expressed in a given type of cell. Therefore, it is critical that the expression patterns of these immune cell types be deciphered in the context of a network, and not as an individual, so that their roles be correctly characterized and related to one another. Defects of the immune system such as autoimmune diseases, immunodeficiency, and malignancies can benefit from genomic insights on pathological processes. For example, analyzing the systematic variation of gene expression can relate these patterns with specific diseases and gene networks important for immune functions.

<span class="mw-page-title-main">Peptide microarray</span>

A peptide microarray is a collection of peptides displayed on a solid surface, usually a glass or plastic chip. Peptide chips are used by scientists in biology, medicine and pharmacology to study binding properties and functionality and kinetics of protein-protein interactions in general. In basic research, peptide microarrays are often used to profile an enzyme, to map an antibody epitope or to find key residues for protein binding. Practical applications are seromarker discovery, profiling of changing humoral immune responses of individual patients during disease progression, monitoring of therapeutic interventions, patient stratification and development of diagnostic tools and vaccines.

Mass spectrometric immunoassay (MSIA) is a rapid method is used to detect and/ or quantify antigens and or antibody analytes. This method uses an analyte affinity isolation to extract targeted molecules and internal standards from biological fluid in preparation for matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS). This method allows for "top down" and "bottom up" analysis. This sensitive method allows for a new and improved process for detecting multiple antigens and antibodies in a single assay. This assay is also capable of distinguishing mass shifted forms of the same molecule via a panantibody, as well as distinguish point mutations in proteins. Each specific form is detected uniquely based on their characteristic molecular mass. MSIA has dual specificity because of the antibody-antigen reaction coupled with the power of a mass spectrometer.

<span class="mw-page-title-main">Molecular diagnostics</span> Collection of techniques used to analyze biological markers in the genome and proteome

Molecular diagnostics is a collection of techniques used to analyze biological markers in the genome and proteome, and how their cells express their genes as proteins, applying molecular biology to medical testing. In medicine the technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients, and in agricultural biosecurity similarly to monitor crop- and livestock disease, estimate risk, and decide what quarantine measures must be taken.

Stable isotope standards and capture by anti-peptide antibodies (SISCAPA) is a mass spectrometry method for measuring the amount of a protein in a biological sample.

Retrogenix is a biotechnology company based in the United Kingdom. Founded by Jim Freeth and Jo Soden in 2008, the company was acquired in April 2021 by Charles River Laboratories and is now known as the ‘High Peak’ site.

Signs Of LIfe Detector (SOLID) is an analytical instrument under development to detect extraterrestrial life in the form of organic biosignatures obtained from a core drill during planetary exploration.

<span class="mw-page-title-main">Olga Ornatsky</span> Canadian Scientist

Olga Ornatsky is a Soviet born, Canadian scientist. Ornatsky co-founded DVS Sciences in 2004 along with Dmitry Bandura, Vladimir Baranov and Scott D. Tanner.

References

  1. ↑ Rivas LA, García-Villadangos M, Moreno-Paz M, Cruz-Gil P, Gómez-Elvira J, Parro V (November 2008). "A 200-antibody microarray biochip for environmental monitoring: searching for universal microbial biomarkers through immunoprofiling". Anal. Chem. 80 (21): 7970–9. doi:10.1021/ac8008093. PMID   18837515.
  2. ↑ Chaga GS (2008). "Antibody Arrays for Determination of Relative Protein Abundances". Tissue Proteomics. Methods in Molecular Biology. Vol. 441. pp. 129–51. doi:10.1007/978-1-60327-047-2_9. ISBN   978-1-58829-679-5. PMID   18370316.
  3. ↑ Wilson J. J.; Burgess R.; Mao Y. Q.; Luo S.; Tang H.; Jones V. S.; et al. (2015). Chapter Seven-Antibody Arrays in Biomarker Discovery. pp. 255–324. doi:10.1016/bs.acc.2015.01.002. ISBN   9780128022658. PMID   25934364.{{cite book}}: |journal= ignored (help)
  4. ↑ Lin Y., Huang R.C., Cao X., Wang S.-M., Shi Q., Huang R.-P. (2003). "Detection of multiple cytokines by protein arrays from cell lysate and tissue lysate". Clin Chem Lab Med. 41 (2): 139–145. doi:10.1515/cclm.2003.023. PMID   12666998. S2CID   34616684.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ↑ Chang TW (December 1983). "Binding of cells to matrixes of distinct antibodies coated on solid surface". J. Immunol. Methods. 65 (1–2): 217–23. doi:10.1016/0022-1759(83)90318-6. PMID   6606681.
  6. ↑ Chang, Tse W. U.S. Patent 4,591,570 "Matrix of antibody-coated spots for determination of antigens", Priority date February 2, 1983
  7. ↑ Chang, Tse W. U.S. Patent 4,829,010 "Immunoassay device enclosing matrixes of antibody spots for cell determinations", Priority date March 13, 1987
  8. ↑ Chang, Tse W. U.S. Patent 5,100,777 "Antibody matrix device and method for evaluating immune status", Priority date April 27, 1987
  9. ↑ Chang TW (March 1993). "Immunosorbent Cytometry". Biotechnology. 11 (3): 291–3. doi:10.1038/nbt0393-291. PMID   7765290. S2CID   35328421.
  10. ↑ Ekins RP (1989). "Multi-analyte immunoassay". J Pharm Biomed Anal. 7 (2): 155–68. doi:10.1016/0731-7085(89)80079-2. PMID   2488616.
  11. ↑ Ekins RP, Chu FW (November 1991). "Multianalyte microspot immunoassay—microanalytical "compact disk" of the future". Clin. Chem. 37 (11): 1955–67. doi:10.1016/0167-7799(94)90111-2. PMID   1934470.
  12. ↑ Ekins RP (September 1998). "Ligand assays: from electrophoresis to miniaturized microarrays". Clin. Chem. 44 (9): 2015–30. doi: 10.1093/clinchem/44.9.2015 . PMID   9733000.
  13. ↑ Jiang, W., Mao, Y. Q., Huang, R., Duan, C., Xi, Y., Yang, K., & Huang, R. P. (2014). "Protein expression profiling by antibody array analysis with use of dried blood spot samples on filter paper". Journal of Immunological Methods. 403 (1): 79–86. doi:10.1016/j.jim.2013.11.016. PMID   24287424.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ↑ Zeng Q., Chen W. (2010). "The functional behavior of a macrophage/fibroblast co-culture model derived from normal and diabetic mice with a marine gelatin–oxidized alginate hydrogel". Biomaterials. 31 (22): 5772–5781. doi:10.1016/j.biomaterials.2010.04.022. PMC   2876200 . PMID   20452666.
  15. ↑ Sohn Elliott H; et al. (2015). "Allogenic iPSC-derived RPE cell transplants induce immune response in pigs: a pilot study". Scientific Reports. 5: 11791. Bibcode:2015NatSR...511791S. doi:10.1038/srep11791. PMC   4490339 . PMID   26138532.
  16. ↑ Silzel J. W., Cercek B., Dodson C., Tsay T., Obremski R. J. (1998). "Mass-sensing, multianalyte microarray immunoassay with imaging detection". Clin. Chem. 44 (9): 2036–2043. doi: 10.1093/clinchem/44.9.2036 . PMID   9733002.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ↑ Mendoza L. G., McQuary P., Mongan A., Gangadharan R., Brignac S., Eggers M. (1999). "High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA)". BioTechniques. 27 (4): 778–788. doi: 10.2144/99274rr01 . PMID   10524321.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  18. ↑ Lueking A., Horn M., Eickhoff H., Bussow K., Lehrach H., Walter G. (1999). "Protein microarrays for gene expression and antibody screening". Anal. Biochem. 270 (1): 103–111. doi:10.1006/abio.1999.4063. PMID   10328771.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  19. ↑ de Wildt, R. M., Mundy, C. R., Gorick, B. D., and Tomlinson, I. M. (2000) Antibody arrays for high-throughput screening of antibody-antigen interactions. Nature Biotechnol. 18, 989 –994
  20. ↑ Holt L. J., Bussow K., Walter G., Tomlinson I. M. (2000). "By-passing selection: Direct screening for antibody–antigen interactions using protein arrays". Nucleic Acids Res. 28 (15): E72. doi:10.1093/nar/28.15.e72. PMC   102691 . PMID   10908365.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  21. ↑ Zhu H., Klemic J. F., Chang S., Bertone P., Casamayor A., Klemic K. G., Smith D., Gerstein M., Reed M. A., Snyder M. (2000). "Analysis of yeast protein kinases using protein chips". Nature Genetics. 26 (3): 283–289. doi:10.1038/81576. PMID   11062466. S2CID   9238048.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  22. ↑ Joos T. O., Schrenk M., Hopfl P., Kroger K., Chowdhury U., Stoll D., Schorner D., Durr M., Herick K., Rupp S., Sohn K., Hammerle H. (2000). "A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics". Electrophoresis. 21 (13): 2641–2650. doi:10.1002/1522-2683(20000701)21:13<2641::aid-elps2641>3.0.co;2-5. PMID   10949141. S2CID   24008668.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  23. ↑ Walter G., Bussow K., Cahill D., Lueking A., Lehrach H. (2000). "Protein arrays for gene expression and molecular interaction screening". Curr. Opin. Microbiol. 3 (3): 298–302. doi:10.1016/s1369-5274(00)00093-x. PMID   10851162.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  24. ↑ Service R. F. (2000). "Biochemistry: Protein arrays step out of DNA's shadow". Science. 289 (5485): 1673. doi:10.1126/science.289.5485.1673. PMID   11001728. S2CID   2753950.
  25. ↑ Wang Y., Wu T. R., Cai S., Welte T., Chin Y. E. (2000). "Stat1 as a Component of Tumor Necrosis Factor Alpha Receptor 1-TRADD Signaling Complex To Inhibit NF-κB Activation". Molecular and Cellular Biology. 20 (13): 4505–4512. doi:10.1128/mcb.20.13.4505-4512.2000. PMC   85828 . PMID   10848577.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  26. ↑ R.-P. Huang. (2001). Simultaneous detection of multiple proteins with an array-based enzyme-linked immunosorbant assay (ELISA) and enhanced chemiluminescence (ECL). Clin. Chem. Lab. Med. 39:209-214.
  27. ↑ Kusnezow W, Banzon V, Schröder C, Schaal R, Hoheisel JD, Rüffer S, Luft P, Duschl A, Syagailo YV (2007). "Antibody microarray-based profiling of complex specimens: systematic evaluation of labeling strategies". Proteomics. 7 (11): 1786–99. doi:10.1002/pmic.200600762. PMID   17474144. S2CID   9852887.
  28. ↑ Kusnezow W, Banzon V, Schröder C, Schaal R, Hoheisel JD, Rüffer S, Luft P, Duschl A, Syagailo YV (2007). "Antibody microarray-based profiling of complex specimens: systematic evaluation of labeling strategies". Proteomics. 7 (11): 1786–99. doi:10.1002/pmic.200600762. PMID   17474144. S2CID   9852887.
  29. ↑ Wingren Christer, Ingvarsson Johan, Dexlin Linda, Szul Dominika, Borrebaeck Carl A. K. (2007). "Design of recombinant antibody microarrays for complex proteome analysis: Choice of sample labeling-tag and solid support". Proteomics. 7 (17): 3055–3065. doi:10.1002/pmic.200700025. PMID   17787036. S2CID   29548647.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  30. ↑ Alhamdani, MS; Schröder, C; Hoheisel, JD (Jul 6, 2009). "Oncoproteomic profiling with antibody microarrays". Genome medicine 1 (7): 68
  31. ↑ Jones V. S., Huang R. Y., Chen L. P., Chen Z. S., Fu L., Huang R. P. (2016). "Cytokines in cancer drug resistance: cues to new therapeutic strategies". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1865 (2): 255–265. doi: 10.1016/j.bbcan.2016.03.005 . PMID   26993403.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ↑ Burkholder B., Burgess R.Y. R., Luo S.H., Jones V.S., Zhang W.J., Lv Z.Q., Gao C.-Y., Wang B.-L., Zhang Y.-M., Huang R.-P. (2014). "Tumor-induced perturbations of cytokines and immune cell networks". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1845 (2): 182–201. doi: 10.1016/j.bbcan.2014.01.004 . PMID   24440852.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  33. ↑ Lin Y.; Luo S.; Shao N.; Wang S.; Duan C.; Burkholder B.; et al. (2013). "Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment". Current Proteomics. 10 (4): 269–277. doi:10.2174/1570164610666131210233343.
  34. ↑ Huang R.-P. (2007). "An array of possibilities in cancer research using cytokine antibody arrays". Expert Review of Proteomics. 4 (2): 299–308. doi:10.1586/14789450.4.2.299. PMID   17425464. S2CID   30102746.
  35. ↑ Schröder C, Jacob A, Tonack S, Radon TP, Sill M, Zucknick M, Rüffer S, Costello E, Neoptolemos JP, Crnogorac-Jurcevic T, Bauer A, Fellenberg K, Hoheisel JD (2010). "Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies". Molecular & Cellular Proteomics. 9 (6): 1271–80. doi:10.1074/mcp.m900419-mcp200. PMC   2877986 . PMID   20164060.
  36. ↑ Huang R., Jiang W., Yang J., Mao Y.Q., Zhang Y., Yang W., Yang D., Burkholder B., Huang R.F., Huang R.P. (2010). "A biotin label-based antibody array for high-content profiling of protein expression". Cancer Genomics Proteomics. 7 (3): 129–41. PMID   20551245.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  37. ↑ Schwartzbaum J.; Seweryn M.; Holloman C.; Harris R.; Handelman S. K.; Rempala G. A.; et al. (2015). "Association between Prediagnostic Allergy-Related Serum Cytokines and Glioma". PLOS ONE. 10 (9): e0137503. Bibcode:2015PLoSO..1037503S. doi: 10.1371/journal.pone.0137503 . PMC   4564184 . PMID   26352148.
  38. ↑ Jaeger P. A.; Lucin K. M.; Britschgi M.; Vardarajan B.; Huang R.-P.; Kirby E. D.; et al. (2016). "Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain". Molecular Neurodegeneration. 11 (1): 31. doi: 10.1186/s13024-016-0105-4 . PMC   4877764 . PMID   27216421.
  39. ↑ RayBiotech, Inc. Antibody Arrays. (2017). Retrieved from the RayBiotech, Inc. website http://www.raybiotech.com/antibody-array.html
  40. ↑ "Sciomics: Antibody meets microarray - scioPhospho". www.sciomics.de. Retrieved 2018-04-24.
  41. ↑ Jiang, W., Mao, Y. Q., Huang, R., Duan, C., Xi, Y., Yang, K., & Huang, R. P. (2014). "Protein expression profiling by antibody array analysis with use of dried blood spot samples on filter paper". Journal of Immunological Methods. 403 (1): 79–86. doi:10.1016/j.jim.2013.11.016. PMID   24287424.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  42. ↑ Decrop Deborah (2017). "Single-Step Imprinting of Femtoliter Microwell Arrays Allows Digital Bioassays with Attomolar Limit of Detection". ACS Applied Materials & Interfaces. 9 (12): 10418–10426. doi:10.1021/acsami.6b15415. PMID   28266828.
  43. ↑ Guo, W; Vilaplana, L; Hansson, J; Marco, P; van der Wijngaart, W (2020). "Immunoassays on thiol-ene synthetic paper generate a superior fluorescence signal". Biosensors and Bioelectronics. 163: 112279. doi:10.1016/j.bios.2020.112279. hdl: 10261/211201 . PMID   32421629. S2CID   218688183.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.